Delving into the Latest Updates on Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Other Diseases

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Autologous CAR-T	1

Top 5 Target	Count

CD276(CD276 antigen)	1

This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

Start Date01 Jun 2023

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+3]

NCT04385173

/ Unknown statusPhase 1IIT

A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

Start Date01 Dec 2022

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+1]

100 Clinical Results associated with Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd.

Login to view more data

100 Deals associated with Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Boyuan Runsheng Pharmaceutical (Hangzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data